167 related articles for article (PubMed ID: 31115564)
1. Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
Xu SG; Yu JJ; Shi Q; Niu Q; Guo Z; Guo BY; Zhou GC; Gu X; Wu YX
Oncol Rep; 2019 Jul; 42(1):273-282. PubMed ID: 31115564
[TBL] [Abstract][Full Text] [Related]
2. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
4. HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo.
Xiang S; Zou P; Tang Q; Zheng F; Wu J; Chen Z; Hann SS
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):589-599. PubMed ID: 29221985
[TBL] [Abstract][Full Text] [Related]
5. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
6. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.
Pan MZ; Song YL; Gao F
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis.
Mao LJ; Zhang J; Liu N; Fan L; Yang DR; Xue BX; Shan YX; Zheng JN
Tumour Biol; 2015 Nov; 36(11):9073-81. PubMed ID: 26084613
[TBL] [Abstract][Full Text] [Related]
12. Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
Xiao Q; Zheng F; Tang Q; Wu JJ; Xie J; Huang HD; Yang XB; Hann SS
Cell Physiol Biochem; 2018; 49(4):1615-1632. PubMed ID: 30223276
[TBL] [Abstract][Full Text] [Related]
13. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
[TBL] [Abstract][Full Text] [Related]
14. MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2.
Song BF; Xu LZ; Jiang K; Cheng F
Funct Integr Genomics; 2023 Mar; 23(2):80. PubMed ID: 36884182
[TBL] [Abstract][Full Text] [Related]
15. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
16. Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer.
Zheng N; Wang L; Hou Y; Zhou X; He Y; Wang Z
Cell Cycle; 2018; 17(21-22):2460-2473. PubMed ID: 30394832
[TBL] [Abstract][Full Text] [Related]
17. Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method.
Shinmei S; Sentani K; Hayashi T; Sakamoto N; Goto K; Oo HZ; Naito Y; Teishima J; Matsubara A; Oue N; Kuniyasu H; Yasui W
Urol Oncol; 2014 Aug; 32(6):769-78. PubMed ID: 24968948
[TBL] [Abstract][Full Text] [Related]
18. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
19. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
Yang F; Lv LZ; Cai QC; Jiang Y
World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
[TBL] [Abstract][Full Text] [Related]
20. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]